Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CD44 antisense RNA 1 (CD44-AS1)
- Target
- CD44-AS1
- Molecular classification
- Long non-coding RNA (lncRNA), Antisense RNA, Other (it is not a protein, receptor, enzyme, or transporter)
01
Overview
CD44 antisense RNA 1 (CD44-AS1) is a long non-coding RNA that is transcribed antisense to the CD44 gene, which encodes a cell surface glycoprotein involved in cell adhesion, migration, and tumor progression[1]. CD44-AS1 modulates CD44 expression, likely through RNA-RNA interactions and possibly through ceRNA (competing endogenous RNA) activity, although functional studies specific to CD44-AS1 are currently limited. Altered regulation of CD44 by related antisense lncRNAs has been implicated in cancer progression, cell migration, and inflammation. While there are no direct therapies targeting CD44-AS1, its modulation of CD44 makes it of interest in understanding the gene regulatory networks involved in cancer and inflammatory diseases[1]. If further research identifies critical and unique roles for CD44-AS1 in disease, it may emerge as an indirect therapeutic target or biomarker candidate in the future.
- Other names
- RP1-68D18.4hLinfRNA5human Long-noncoding inflammation associated RNA 5
02
Mechanism of action
Not directly druggable. As a regulatory RNA, CD44-AS1 modulates CD44 expression, likely through antisense pairing that may affect CD44 messenger RNA stability, transcription, or splicing.
03
Biological functions
Regulation of CD44 gene expression (via antisense mechanisms)Post-transcriptional gene regulation (by acting as ceRNA, or competing endogenous RNA)Possible roles in cell proliferation, migration, and invasion in cancer (as inferred from related lncRNAs)
04
Disease associations
Cancer (based on the regulatory relationship to CD44 and the known function of antisense lncRNAs)Inflammation (as suggested by the alias "human Long-noncoding inflammation associated RNA 5")
05
Safety considerations
None established for direct targeting. General challenges would involve the delivery, specificity, and off-target effects of lncRNA-targeted therapeutics.
06
Biomarkers
No established clinical biomarkers specifically for CD44-AS1, but altered CD44-AS1 expression could theoretically be used as a biomarker in research settings for cancer or inflammation linked to CD44 pathway activation.
Beyond the preview
Go deeper on CD44 antisense RNA 1 (CD44-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD44 antisense RNA 1 (CD44-AS1).